About HLA class I histocompatibility antigen, C alpha chain
HLA class I histocompatibility antigen, C alpha chain (HLA-C) is a protein
from Homo sapiens identified by UniProt accession
P10321, 366 residues long.
MolForge cross-references it against 0 known binders and
989 disease associations.
Target properties
| Protein name | HLA class I histocompatibility antigen, C alpha chain |
|---|
| UniProt accession | P10321 |
|---|
| Gene | HLA-C |
|---|
| Organism | Homo sapiens |
|---|
| Length | 366 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (989)
Diseases linked to this target (Open Targets).
- lymphocyte count · score 0.56
- leukocyte count · score 0.55
- COVID-19 · score 0.49
- psoriasis · score 0.46
- blood protein measurement · score 0.40
- mean corpuscular volume · score 0.39
- BMI-adjusted waist-hip ratio · score 0.38
- neutrophil count · score 0.38
- monocyte count · score 0.37
- psoriatic arthritis · score 0.36
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P10321-F1 | alphafold | PREDICTED | 86.45 | — |
Amino-acid sequence (366 residues)
MRVMAPRALL LLLSGGLALT ETWACSHSMR YFDTAVSRPG RGEPRFISVG YVDDTQFVRF DSDAASPRGE PRAPWVEQEG PEYWDRETQK YKRQAQADRV SLRNLRGYYN QSEDGSHTLQ RMSGCDLGPD GRLLRGYDQS AYDGKDYIAL NEDLRSWTAA DTAAQITQRK LEAARAAEQL RAYLEGTCVE WLRRYLENGK ETLQRAEPPK THVTHHPLSD HEATLRCWAL GFYPAEITLT WQRDGEDQTQ DTELVETRPA GDGTFQKWAA VVVPSGQEQR YTCHMQHEGL QEPLTLSWEP SSQPTIPIMG IVAGLAVLVV LAVLGAVVTA MMCRRKSSGG KGGSCSQAAC SNSAQGSDES LITCKA
Explore HLA class I histocompatibility antigen, C alpha chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets